These data indicate that the protective role of IL-17 in maintaining the intestinal barrier perhaps outweighs its tissue-damaging potential in NAFLD/NASH, similar to the conditions in IBD (27). Here, IL17A is linked to metabolic dysfunction-associated steatotic liver disease.